This page shows the latest IL-13 inhibitor news and features for those working in and with pharma, biotech and healthcare.
The IL-13 inhibitor improved the symptoms of atopic dermatitis for up to two years. ... study of the IL-13 inhibitor.
Almirall has announced that its IL-13 inhibitor lebrikizumab has been recommended by the European Medicines Agency’s human medicines committee to treat moderate-to-severe atopic dermatitis.
Almirall has revealed topline results from its one-year analysis of the efficacy and safety of its investigational IL-13 inhibitor, lebrikizumab, to treat patients with moderate-to-severe atopic dermatitis ... Lebrikizumab is a novel, monoclonal antibody
The pharma giant is also set to gain an additional phase 3 candidate from the deal – lebrikizumab, a monoclonal antibody designed to bind to IL-13 that is being evaluated for ... Dermira gained the bulk of the rights to the IL-13 inhibitor in a
Atopic dermatitis was poorly-served with therapies for years, but latterly has seen new treatment options come to market including Sanofi and Regeneron’s IL-4 and IL-13 inhibitor Dupixent ... There are a number of drugs coming through the collective
Dupixent – an IL-4 and IL-13 inhibitor that is one of the fast-growing drugs in both Sanofi and Regeneron’s portfolios – is already approved in the US for atopic
More from news
Approximately 1 fully matching, plus 25 partially matching documents found.
No results were found
Not just another healthcare communications agency. We are a collection of award-winning industry experts focusing on bringing the very best...